46 results on '"Crotti, Lia"'
Search Results
2. Contributors
- Author
-
Aagaard, Philip, primary, Abrams, Dominic James, additional, Abriel, Hugues, additional, Adkisson, Wayne O., additional, Agullo-Pascual, Esperanza, additional, Alvarado, Francisco J., additional, Amin, Ahmad S., additional, Antzelevitch, Charles, additional, Anumonwo, Justus M.B., additional, Armaganijan, Luciana, additional, Arya, Arash, additional, Asirvatham, Samuel, additional, Atienza, Felipe, additional, Backx, Peter H., additional, Ballou, Lisa M., additional, Balse, Elise, additional, Balulad, Sujata, additional, Barbuti, Andrea, additional, Bardy, Gust H., additional, Bassil, Guillaume, additional, Benditt, David G., additional, Berenfeld, Omer, additional, Bers, Donald M., additional, Binah, Ofer, additional, Bogun, Frank, additional, Bongianino, Rossana, additional, Boyle, Noel G., additional, Boyle, Patrick M., additional, Breithardt, Günter, additional, Brini, Marisa, additional, Brink, Peter R., additional, Brugada, Pedro, additional, Buch, Eric, additional, Bukauskas, Feliksas F., additional, Calkins, Hugh, additional, Callans, David J., additional, Caples, Sean M., additional, Carafoli, Ernesto, additional, Catterall, William A., additional, Cerrone, Marina, additional, Chaumeil, Arnaud, additional, Chen, Caressa, additional, Chen, Lan S., additional, Chen, Peng-Sheng, additional, Cheng, Jianding, additional, Chiamvimonvat, Nipavan, additional, Christini, David J., additional, Chugh, Aman, additional, Climent, Andreu M., additional, Cohen, Ira S., additional, Connolly, Stuart J., additional, Cooper, Lebron, additional, Crespo, Eric M., additional, Crotti, Lia, additional, Csepe, Thomas A., additional, Cuoco, Frank, additional, Curtis, Anne B., additional, Damiano, Ralph J., additional, Darbar, Dawood, additional, Das, Mithilesh K., additional, d’Avila, Andre, additional, Delmar, Mario, additional, Delpón, Eva, additional, Denegri, Marco, additional, Denis, Arnaud, additional, Derval, Nicolas, additional, Deschênes, Isabelle, additional, Deshmukh, Abhishek, additional, Di Biase, Luigi, additional, Dickfeld, Timm M., additional, Dierckx, Hans, additional, Dinov, Borislav, additional, Dixit, Sanjay, additional, Dobrev, Dobromir, additional, Dubois, Remi, additional, Eckardt, Lars, additional, Edwards, Andrew G., additional, Ellenbogen, Kenneth A., additional, Ellinor, Patrick T., additional, Estes, N.A. Mark, additional, Fabritz, Larissa, additional, Fedorov, Vadim V., additional, Fernandez, Antonio B., additional, Teijeira Fernández, Elvis, additional, Filgueiras-Rama, David, additional, Fishbein, Michael C., additional, Fishman, Glenn I., additional, Frankel, David S., additional, Friedman, Paul, additional, Frontera, Antonio, additional, Gami, Apoor S., additional, Garabelli, Paul, additional, George, Alfred L., additional, Gerstenfeld, Edward P., additional, Gizurarson, Sigfus, additional, Gold, Michael R., additional, Goldberger, Jeffrey J., additional, Grace, Andrew, additional, Grassi, Guido, additional, Greenfield, Ruth Ann, additional, Gross, Wendy L., additional, Grubb, Blair P., additional, Guillem, María S., additional, Györke, Sándor, additional, Haïssaguerre, Michel, additional, Hake, Johan, additional, Halperin, Henry R., additional, Hansen, Brian J., additional, Hatem, Stéphane, additional, Hayes, David L., additional, Heijman, Jordi, additional, Herron, Todd J., additional, Hindricks, Gerhard, additional, Hocini, Mélèze, additional, Hohnloser, Stefan H., additional, Holmes, David R., additional, Hoshijima, Masahiko, additional, Hund, Thomas J., additional, Hutchinson, Mathew D., additional, Ilkhanoff, Leonard, additional, Ingles, Jodie, additional, Ip, James E., additional, Jackman, Warren M., additional, Jackson, Nicholas, additional, Jaïs, Pierre, additional, Jalife, José, additional, Jhun, Bong Sook, additional, John, Roy M., additional, Jongbloed, Monique, additional, Jordaens, Luc, additional, Kalman, Jonathan M., additional, Kamp, Timothy J., additional, Kanj, Mohamed H., additional, Kapa, Suraj, additional, Karabin, Beverly, additional, Karakikes, Ioannis, additional, Katritsis, Demosthenes G., additional, Kaur, Kuljeet, additional, Kirchhof, Paulus, additional, Kléber, André G., additional, Klein, George J., additional, Kohl, Peter, additional, Koneru, Jayanthi N., additional, Koruth, Jacob S., additional, Krahn, Andrew D., additional, Krogh-Madsen, Trine, additional, Kuck, Karl Heinz, additional, Kumar, Saurabh, additional, Kushnir, Alexander, additional, Lakdawala, Neal K., additional, Laksman, Zachary W.M., additional, Latchamsetty, Rakesh, additional, Lau, Dennis H., additional, Lerman, Bruce B., additional, Lin, Richard Z., additional, Lin, Shien-Fong, additional, Link, Mark S., additional, Liu, Bin, additional, Liu, Christopher F., additional, Lockwood, Deborah J., additional, Lopatin, Anatoli N., additional, Lubitz, Steven A., additional, Mahajan, Rajiv, additional, Makielski, Jonathan C., additional, Malik, Marek, additional, Marchlinski, Francis E., additional, Markowitz, Steven M., additional, Maron, Barry J., additional, Maron, Martin S., additional, Marx, Steven O., additional, Massé, Stéphane, additional, McCulloch, Andrew D., additional, McKelvie-Sebileau, Pippa, additional, Melby, Spencer J., additional, Metzner, Andreas, additional, Michailova, Anushka P., additional, Michaud, Gregory F., additional, Miller, John M., additional, Mishra, Jyotsna, additional, Mitrani, Raul D., additional, Mohler, Peter J., additional, Morady, Fred, additional, Myerburg, Robert J., additional, Nakagawa, Hiroshi, additional, Nalliah, Chrishan Joseph, additional, Nanthakumar, Kumaraswamy, additional, Napolitano, Carlo, additional, Narayan, Sanjiv M., additional, Natale, Andrea, additional, Nattel, Stanley, additional, Nazarian, Saman, additional, Nguyen, Thao P., additional, Nogami, Akihiko, additional, Noujaim, Sami F., additional, Nubret Le Coniat, Karine, additional, Olshansky, Brian, additional, O-Uchi, Jin, additional, Oudit, Gavin Y., additional, Ouyang, Feifan, additional, Ozcan, Cevher, additional, Packer, Douglas L., additional, Pandit, Sandeep V., additional, Panfilov, Alexander V., additional, Park, David S., additional, Patocskai, Bence, additional, Pauza, Dainius H., additional, Pauziene, Neringa, additional, Piccini, Jonathan P., additional, Pitt, Geoffrey S., additional, Po, Sunny S., additional, Prasad, Abhiram, additional, Priori, Silvia G., additional, Radwański, Przemysław B., additional, Rappel, Wouter-Jan, additional, Reiser, Michelle, additional, Restrepo, Alejandro Jimenez, additional, Robinson, Richard B., additional, Roden, Dan M., additional, Rosen, Michael R., additional, Rosso, Raphael, additional, Rudy, Yoram, additional, Rysevaite-Kyguoliene, Kristina, additional, Sabbah, Hani N., additional, Sacher, Frederic, additional, Sachse, Frank B., additional, Saguner, Ardan M., additional, Sanders, Prashanthan, additional, Sanguinetti, Michael C., additional, Santangeli, Pasquale, additional, Sarraf, Mohammad, additional, Satin, Jonathan, additional, Schalij, Martin Jan, additional, Scherlag, Benjamin J., additional, Schill, Matthew R., additional, Schleifer, J. William, additional, Schuessler, Richard B., additional, Schwartz, Peter J., additional, Seeger, Timon, additional, Semsarian, Christopher, additional, Seravalle, Gino, additional, Shah, Ashok J., additional, Shaw, Robin M., additional, Shen, Mark J., additional, Shen, Win–Kuang, additional, Sheu, Shey-Shing, additional, Shivkumar, Kalyanam, additional, Silva, Jennifer N.A., additional, Skanes, Allan C., additional, Soejima, Kyoko, additional, Somers, Virend K., additional, Sorajja, Dan, additional, Stavrakis, Stavros, additional, Steinberg, Christian, additional, Stevenson, Lynne Warner, additional, Stevenson, William G., additional, Sweeney, Michael O., additional, Swerdlow, Charles, additional, Takigawa, Masateru, additional, Tamargo, Juan, additional, Tandri, Harikrishna, additional, Tedrow, Usha B., additional, Thompson, Nathaniel, additional, Thompson, Paul D., additional, Tomaselli, Gordon F., additional, Towbin, Jeffrey A., additional, Trayanova, Natalia A., additional, Tristani-Firouzi, Martin, additional, Tseng, Zian H., additional, Ueda, Akiko, additional, Valdivia, Héctor H., additional, Valiunas, Virginijus, additional, van der Werf, Christian, additional, Van Hare, George F., additional, Vidmar, David, additional, Viskin, Sami, additional, Voigt, Niels, additional, Walsh, Edward P., additional, Wang, Paul J., additional, Wehrens, Xander H.T., additional, Weiss, Mark S., additional, Wilde, Arthur A.M., additional, Wilkoff, Bruce L., additional, Woo, Y. Joseph, additional, Wu, Joseph C., additional, Yee, Raymond, additional, Zaman, Junaid A.B., additional, Zarzoso, Manuel, additional, Zeitler, Emily P., additional, Zeppenfeld, Katja, additional, Zghaib, Tarek, additional, Zhang, Xiao-Dong, additional, and Zipes, Douglas P., additional
- Published
- 2018
- Full Text
- View/download PDF
3. Contributors
- Author
-
Abriel, Hugues, primary, Adkisson, Wayne O., additional, Agullo-Pascual, Esperanza, additional, Ajijola, Olujimi A., additional, Al-Ahmad, Amin, additional, Alli, Oluseun, additional, Altman, Robert K., additional, Anter, Elad, additional, Antzelevitch, Charles, additional, Anumonwo, Justus M.B., additional, Armaganijan, Luciana, additional, Ashikaga, Hiroshi, additional, Atienza, Felipe, additional, Avula, Uma Mahesh R., additional, Backx, Peter H., additional, Balse, Elise, additional, Barrett, Conor D., additional, Benditt, David G., additional, Berenfeld, Omer, additional, Bers, Donald M., additional, Berul, Charles I., additional, Blank, A. Christian, additional, Bloise, Raffaella, additional, Bogun, Frank Matthias, additional, Borggrefe, Martin, additional, Boyle, Noel G., additional, Breithardt, Günter, additional, Brini, Marisa, additional, Brink, Peter R., additional, Brugada, Josep, additional, Brugada, Pau, additional, Brugada, Pedro, additional, Brugada, Ramon, additional, Brugada, Victoria, additional, Buch, Eric, additional, Bukauskas, Feliksas F., additional, Burkhardt, J. David, additional, Bursac, Nenad, additional, Calkins, Hugh, additional, Callans, David J., additional, Campuzano, Oscar, additional, Caples, Sean M., additional, Carafoli, Ernesto, additional, Castellanos, Augustin, additional, Catterall, William, additional, Cerrone, Marina, additional, Chen, Lan S., additional, Chen, Lei, additional, Chen, Peng-Sheng, additional, Chin, Ashley, additional, Chugh, Aman, additional, Cohen, Ira S., additional, Connolly, Stuart J., additional, Constantino, Jason, additional, Crotti, Lia, additional, Cuoco, Frank A., additional, Curtis, Anne B., additional, Damiano, Ralph J., additional, Darbar, Dawood, additional, Das, Mithilesh K., additional, Delmar, Mario, additional, Delpón, Eva, additional, Di Biase, Luigi, additional, Dixit, Sanjay, additional, Dobrev, Dobromir, additional, Dosdall, Derek J., additional, Dyer, John W., additional, Eckardt, Lars, additional, Edwards, Andrew G., additional, Efimov, Igor R., additional, Ellenbogen, Kenneth A., additional, Ellinor, Patrick T., additional, Entcheva, Emilia, additional, Estes, N.A. Mark, additional, Fischmeister, Rodolphe, additional, Fisher, John D., additional, Fishman, Glenn I., additional, Frankel, David S., additional, Franz, Michael R., additional, Friedman, Paul A., additional, Froelicher, Victor F., additional, Gami, Apoor S., additional, George, Alfred L., additional, Gerstenfeld, Edward P., additional, Gold, Michael R., additional, Goldberger, Jeffrey J., additional, Grandi, Eleonora, additional, Gray, Richard A., additional, Groh, William J., additional, Grubb, Blair P., additional, Haissaguerre, Michel, additional, Hake, Johan, additional, Halperin, Henry R., additional, Harris, Louise, additional, Hatem, Stéphane, additional, Hayes, David L., additional, Hocini, Meleze, additional, Hohnloser, Stefan H., additional, Holmes, David Richard, additional, Hoshijima, Masahiko, additional, Hu, Yuxuan, additional, Hund, Thomas J., additional, Hutchinson, Mathew D., additional, Hwang, Hye Jin, additional, Ideker, Raymond E., additional, Ilkhanoff, Leonard, additional, Ingles, Jodie, additional, Jackman, Warren M., additional, Jais, Pierre, additional, Jalife, José, additional, Jhun, Bong Sook, additional, John, Roy M., additional, Jongbloed, Monique, additional, Josephson, Mark E., additional, Kadish, Alan H., additional, Kalifa, Jérôme, additional, Kalman, Jonathan M., additional, Kamp, Timothy J., additional, Kanj, Mohamed Hani, additional, Karabin, Beverly, additional, Kass, Robert S., additional, Katritsis, Demosthenes G., additional, Kaur, Kuljeet, additional, Kim, Jong J., additional, Kirchhof, Paulus, additional, Kléber, André G., additional, Klein, George J., additional, Kohl, Peter, additional, Kolandaivelu, Aravindan, additional, Krahn, Andrew D., additional, Krumerman, Andrew, additional, Kumar, Saurabh, additional, Kuck, Karl-Heinz, additional, Lakatta, Edward G., additional, Latchamsetty, Rakesh, additional, Lau, Dennis H., additional, Lerman, Bruce B., additional, Leroy, Jérôme, additional, Lewis, William R., additional, Lin, Shien-Fong, additional, Link, Mark S., additional, Liu, Christopher F., additional, Lockwood, Deborah J., additional, Loh, Peter, additional, Lopatin, Anatoli N., additional, Lopshire, John C., additional, Lubitz, Steven A., additional, Madias, Christopher, additional, Mahajan, Aman, additional, Makielski, Jonathan C., additional, Malik, Marek, additional, Maltsev, Victor A., additional, Marchlinski, Francis E., additional, Marelli, Ariane J., additional, Markowitz, Steven M., additional, Maron, Barry J., additional, Martens, Jeffrey R., additional, Marx, Steven O., additional, McCulloch, Andrew D., additional, Metzner, Andreas, additional, Michailova, Anuska P., additional, Miller, John Michael, additional, Milstein, Michelle Lynne, additional, Mohler, Peter, additional, Morady, Fred, additional, Myerburg, Robert J., additional, Nakagawa, Hiroshi, additional, Napolitano, Carlo, additional, Narayan, Sanjiv M., additional, Natale, Andrea, additional, Nattel, Stanley, additional, Nazarian, Saman, additional, Nerbonne, Jeanne M., additional, Ng, Fu Siong, additional, Nogami, Akihiko, additional, Noujaim, Sami F., additional, Olshansky, Brian, additional, Oral, Hakan, additional, O-Uchi, Jin, additional, Ouyang, Feifan, additional, Ozcan, Cevher, additional, Packer, Douglas L., additional, Pahlm, Olle, additional, Pandit, Sandeep V., additional, Park, David S., additional, Pitt, Geoffrey S., additional, Po, Sunny S., additional, Priori, Silvia G., additional, Rappel, Wouter-Jan, additional, Reddy, Vivek Y., additional, Robertson, Jason O., additional, Robinson, Richard B., additional, Roden, Dan M., additional, Rose, Robert A., additional, Rosen, Michael R., additional, Rosso, Raphael, additional, Rudy, Yoram, additional, Ruskin, Jeremy N., additional, Sabbah, Hani N., additional, Sachse, Frank B., additional, Saint, Lindsey L., additional, Saiz, Javier, additional, Sánchez-Chapula, José A., additional, Sanders, Prashanthan, additional, Sanguinetti, Michael C., additional, Santangeli, Pasquale, additional, Sarquella-Brugada, Georgia, additional, Satin, Jonathan, additional, Schalij, Martin Jan, additional, Scherlag, Benjamin J., additional, Schimpf, Rainer, additional, Schmidt, Georg, additional, Schwartz, Peter J., additional, Semsarian, Christopher, additional, Shah, Ashok J., additional, Shaw, Robin, additional, Sheu, Shey Shing, additional, Shivkumar, Kalyanam, additional, Skanes, Allan C., additional, Somers, Virend K., additional, Stambler, Bruce S., additional, Stein, Adam B., additional, Stevenson, Lynne Warner, additional, Stevenson, William G., additional, Sun, Jian, additional, Sutton, Richard, additional, Sweeney, Michael O., additional, Swerdlow, Charles, additional, Tamargo, Juan, additional, Tandri, Harikrishna, additional, Tawil, Rabi, additional, Tedrow, Usha, additional, Terrenoire, Cecile, additional, Tobón, Catalina, additional, Towbin, Jeffrey A., additional, Trayanova, Natalia A., additional, Tristani-Firouzi, Martin, additional, Trohman, Richard G., additional, Tseng, Zian H., additional, Turakhia, Mintu P., additional, Vaidyanathan, Ravi, additional, Valdivia, Héctor H., additional, Valiunas, Virginijus, additional, van der Heyden, Marcel A.G., additional, van der Werf, Christian, additional, Van, George F., additional, Vaseghi, Marmar, additional, Veltmann, Christian, additional, Vetter, Victoria L., additional, Viskin, Sami, additional, Voigt, Niels, additional, Vos, Marc A., additional, Wagner, Galen S., additional, Wang, Paul J., additional, Weerasooriya, Rukshen, additional, Wilde, Arthur A.M., additional, Wilkoff, Bruce L., additional, Wissner, Erik, additional, Woo, Y. Joseph, additional, Yamazaki, Masatoshi, additional, Yang, Felix, additional, Yaniv, Yael, additional, Yap, Sing-Chien, additional, Yee, Raymond, additional, Zarzoso, Manuel, additional, Zeppenfeld, Katja, additional, and Zipes, Douglas P., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Long and Short QT Syndromes
- Author
-
Schwartz, Peter J., primary and Crotti, Lia, additional
- Published
- 2014
- Full Text
- View/download PDF
5. Corrigendum to 'Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management' [International Journal of Cardiology, 2023, 41:180-186].
- Author
-
Brignole M, Cecchi F, Anastasakis A, Crotti L, Deharo JC, Elliott PM, Fedorowski A, Kaski JP, Limongelli G, Maron MS, Olivotto I, Ommen SR, Parati G, Shen W, Ungar A, and Wilde A
- Published
- 2024
- Full Text
- View/download PDF
6. The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action.
- Author
-
Marijon E, Narayanan K, Smith K, Barra S, Basso C, Blom MT, Crotti L, D'Avila A, Deo R, Dumas F, Dzudie A, Farrugia A, Greeley K, Hindricks G, Hua W, Ingles J, Iwami T, Junttila J, Koster RW, Le Polain De Waroux JB, Olasveengen TM, Ong MEH, Papadakis M, Sasson C, Shin SD, Tse HF, Tseng Z, Van Der Werf C, Folke F, Albert CM, and Winkel BG
- Subjects
- Humans, Government, Health Facilities, Interdisciplinary Studies, Death, Sudden, Cardiac prevention & control, Cardiovascular Agents
- Abstract
Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD) continues to be an enormous medical and societal challenge, claiming millions of lives every year. Efforts to prevent SCD are hampered by imperfect risk prediction and inadequate solutions to specifically address arrhythmogenesis. Although resuscitation strategies have witnessed substantial evolution, there is a need to strengthen the organisation of community interventions and emergency medical systems across varied locations and health-care structures. With all the technological and medical advances of the 21st century, the fact that survival from sudden cardiac arrest (SCA) remains lower than 10% in most parts of the world is unacceptable. Recognising this urgent need, the Lancet Commission on SCD was constituted, bringing together 30 international experts in varied disciplines. Consistent progress in tackling SCD will require a completely revamped approach to SCD prevention, with wide-sweeping policy changes that will empower the development of both governmental and community-based programmes to maximise survival from SCA, and to comprehensively attend to survivors and decedents' families after the event. International collaborative efforts that maximally leverage and connect the expertise of various research organisations will need to be prioritised to properly address identified gaps. The Commission places substantial emphasis on the need to develop a multidisciplinary strategy that encompasses all aspects of SCD prevention and treatment. The Commission provides a critical assessment of the current scientific efforts in the field, and puts forth key recommendations to challenge, activate, and intensify efforts by both the scientific and global community with new directions, research, and innovation to reduce the burden of SCD worldwide., Competing Interests: Declaration of interests CMA declares grants from St Jude Medical Foundation and NIH–NHLBI; consulting fees from Medtronic, Illumina, and Novartis; payment or honoraria for lectures from Medtronic; and participation on a data safety monitoring board or advisory board for Medtronic, Element Science, and Boston Scientific. J-BLPDW declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medtronic, Biotronik, Boston Scientific, and Abbott. MTB declares grants from the EU ESCAPE-NET project, funded by the EU's Horizon 2020 research and innovation programme under grant agreement 733381; and grants from European Foundation for the Study of Diabetes (for project Improvement of CVD risk stratification: an innovative method for optimal timing of ECG monitoring). LC declares grants from Grant Horizon 2020 (2016–22) ESCAPE-NET; ERA-CVD Empathy (2020–23) for the electromechanical presages of sudden cardiac death in the young: integrating imaging, modelling, and genetics for patient stratification; grants from AIFA (2020–23) for novel therapy for the long QT syndrome type 2 based on the mechanism of action of the disease-causing mutations; grants from EJP RD (European Joint Program on Rare Disesase) LQTS-NEXT (2020–23) to the next level of risk prediction in patients with long QT syndrome; grants from EJP RD Silence-LQTS (2021–24) for SGK1 inhibition as a novel therapeutic approach in long QT syndrome; and participation on a data safety monitoring board or advisory board for Bristol Myers Squibb. FF declares grants and support for attending meetings or travel from Novo Nordisk Foundation NNF19OC0055142. GH declares grants from European Commission (PROFID project public grant for the development of a risk stratification tool to predict SCD and to evaluate the risk predictor in a clinical trial; NCT04540289) and German Federal Joint Committee (G-BA; RESET CRT public grant for a clinical trial comparing CRT-D versus CRT-P). JI declares research support from National Health and Medical Research Council Australia, Heart Foundation Australia, and New South Wales Health. JJ declares grants from Academy of Finland, Finnish Foundation for Cardiovascular Research, and Sigrid Juselius Foundation; support for attending meetings and travel from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, and Orion Pharma; and participation on a data safety monitoring board or advisory board for Novo Nordisk, Bayer, and Boehringer Ingelheim. EM declares research grants from Abbott, Biotronik, Boston Scientific, Medtronic, MicroPort, and Zoll; consulting fees from Medtronic, Boston Scientific, Zoll, and Abbott; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medtronic, Boston Scientific, Zoll, and Abbott. MEHO declares other financial or non-financial interests from TIIM Healthcare and Global Healthcare SG. TMO declares participation on a data safety monitoring board for the COCA trial (a randomised controlled trial evaluating calcium during cardiac arrest). MP declares grants from St George's, University of London for research on cardiac risk in the young and consulting fees from Bristol Myers Squibb. CS declares being an employee at American Heart Association. H-FT declares research grants from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Novartis, Pfizer, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi; and support for attending meetings and travel from Boehringer Ingelheim. ZT declares grants or contracts from National Institutes of Health (NIH) and National Heart, Lung, and Blood Institute (NHLBI; NIH/NHLBI R01 HL 102090, NIH/NHLBI R01 HL 126555, NIH/NHLBI R01 HL 147035, and NIH/NHLBI R01 HL 157247), NIH and National Institute of Allergy and Infectious Diseases (NIAID; NIH/NIAID P01 AI 169606), and Centers for Disease Control and Prevention (6 NU38DP000019-01-01 and 1 NU38DP000019-01-00). All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Continuous Bayesian variant interpretation accounts for incomplete penetrance among Mendelian cardiac channelopathies.
- Author
-
O'Neill MJ, Sala L, Denjoy I, Wada Y, Kozek K, Crotti L, Dagradi F, Kotta MC, Spazzolini C, Leenhardt A, Salem JE, Kashiwa A, Ohno S, Tao R, Roden DM, Horie M, Extramiana F, Schwartz PJ, and Kroncke BM
- Subjects
- Humans, Mutation, Penetrance, Bayes Theorem, Arrhythmias, Cardiac genetics, KCNQ1 Potassium Channel genetics, Channelopathies genetics
- Abstract
Purpose: The congenital Long QT Syndrome (LQTS) and Brugada Syndrome (BrS) are Mendelian autosomal dominant diseases that frequently precipitate fatal cardiac arrhythmias. Incomplete penetrance is a barrier to clinical management of heterozygotes harboring variants in the major implicated disease genes KCNQ1, KCNH2, and SCN5A. We apply and evaluate a Bayesian penetrance estimation strategy that accounts for this phenomenon., Methods: We generated Bayesian penetrance models for KCNQ1-LQT1 and SCN5A-LQT3 using variant-specific features and clinical data from the literature, international arrhythmia genetic centers, and population controls. We analyzed the distribution of posterior penetrance estimates across 4 genotype-phenotype relationships and compared continuous estimates with ClinVar annotations. Posterior estimates were mapped onto protein structure., Results: Bayesian penetrance estimates of KCNQ1-LQT1 and SCN5A-LQT3 are empirically equivalent to 10 and 5 clinically phenotype heterozygotes, respectively. Posterior penetrance estimates were bimodal for KCNQ1-LQT1 and KCNH2-LQT2, with a higher fraction of missense variants with high penetrance among KCNQ1 variants. There was a wide distribution of variant penetrance estimates among identical ClinVar categories. Structural mapping revealed heterogeneity among "hot spot" regions and featured high penetrance estimates for KCNQ1 variants in contact with calmodulin and the S6 domain., Conclusions: Bayesian penetrance estimates provide a continuous framework for variant interpretation., Competing Interests: Conflict of Interest The authors declare no conflict of interest., (Copyright © 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Corrigendum to "Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis" [International Journal of Cardiology Volume 357, 15 June 2022, Pages 88-94].
- Author
-
Mascia G, Crotti L, Groppelli A, Canepa M, Merlo AC, Benenati S, Di Donna P, Bona RD, Soranna D, Zambon A, Porto I, Olivotto I, Parati G, Brignole M, and Cecchi F
- Published
- 2023
- Full Text
- View/download PDF
9. Corrigendum to "Molecular genetic testing in athletes: Why and when a position statement from the Italian Society of Sports Cardiology" [International Journal of Cardiology Volume 364, 1 October 2022, Pages 169-177].
- Author
-
Castelletti S, Zorzi A, Ballardini E, Basso C, Biffi A, Brancati F, Cavarretta E, Crotti L, Contursi M, D'Aleo A, D'Ascenzi F, Delise P, Dello Russo A, Gazale G, Mos L, Novelli V, Palamà Z, Palermi S, Palmieri V, Patrizi G, Pelliccia A, Pilichou K, Romano S, Sarto P, Schwartz PJ, Tiberi M, Zeppilli P, Corrado D, and Sciarra L
- Published
- 2023
- Full Text
- View/download PDF
10. Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management.
- Author
-
Brignole M, Cecchi F, Anastasakis A, Crotti L, Deharo JC, Elliott PM, Fedorowski A, Kaski JP, Limongelli G, Maron MS, Olivotto I, Ommen SR, Parati G, Shen W, Ungar A, and Wilde A
- Subjects
- Humans, Risk Assessment, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac prevention & control, Death, Sudden, Cardiac etiology, Syncope diagnosis, Syncope etiology, Syncope therapy, Risk Factors, Defibrillators, Implantable adverse effects, Cardiomyopathy, Hypertrophic complications, Cardiomyopathy, Hypertrophic diagnosis, Cardiomyopathy, Hypertrophic therapy
- Abstract
Syncopal events in patients with hypertrophic cardiomyopathy (HCM) are of concern as they are a vital consideration in algorithms for risk stratification for sudden cardiac death (SCD) and ICD implantation. However, the cause of syncope is often under-investigated and/or unexplained. Current syncope guidelines do not provide a detailed definition of unexplained syncope. To address this important gap, an international panel of experts in the field of both syncope and HCM wrote a consensus document with the aim of providing practical guidance for the diagnosis and management of syncope in patients with HCM., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Molecular genetic testing in athletes: Why and when a position statement from the Italian Society of Sports Cardiology.
- Author
-
Castelletti S, Zorzi A, Ballardini E, Basso C, Biffi A, Brancati F, Cavarretta E, Crotti L, Contursi M, D'Aleo A, D'Ascenzi F, Delise P, Dello Russo A, Gazale G, Mos L, Novelli V, Palamà Z, Palermi S, Palmieri V, Patrizi G, Pelliccia A, Pilichou K, Romano S, Sarto P, Schwartz PJ, Tiberi M, Zeppilli P, Corrado D, and Sciarra L
- Subjects
- Arrhythmias, Cardiac, Athletes, Death, Sudden, Cardiac prevention & control, Electrocardiography, Humans, Molecular Biology, Cardiology, Sports physiology
- Abstract
Molecular genetic testing is an increasingly available test to support the clinical diagnosis of inherited cardiovascular diseases through identification of pathogenic gene variants and to make a preclinical genetic diagnosis among proband's family members (so-called "cascade family screening"). In athletes, the added value of molecular genetic testing is to assist in discriminating between physiological adaptive changes of the athlete's heart and inherited cardiovascular diseases, in the presence of overlapping phenotypic features such as ECG changes, imaging abnormalities or arrhythmias ("grey zone"). Additional benefits of molecular genetic testing in the athlete include the potential impact on the disease risk stratification and the implications for eligibility to competitive sports. This position statement of the Italian Society of Sports Cardiology aims to guide general sports medical physicians and sports cardiologists on clinical decision as why and when to perform a molecular genetic testing in the athlete, highlighting strengths and weaknesses for each inherited cardiovascular disease at-risk of sudden cardiac death during sport. The importance of early (preclinical) diagnosis to prevent the negative effects of exercise on phenotypic expression, disease progression and worsening of the arrhythmogenic substrate is also addressed., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
12. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases.
- Author
-
Wilde AAM, Semsarian C, Márquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, Sternick EB, Barajas-Martinez H, Behr ER, Bezzina CR, Breckpot J, Charron P, Chockalingam P, Crotti L, Gollob MH, Lubitz S, Makita N, Ohno S, Ortiz-Genga M, Sacilotto L, Schulze-Bahr E, Shimizu W, Sotoodehnia N, Tadros R, Ware JS, Winlaw DS, Kaufman ES, Aiba T, Bollmann A, Choi JI, Dalal A, Darrieux F, Giudicessi J, Guerchicoff M, Hong K, Krahn AD, MacIntyre C, Mackall JA, Mont L, Napolitano C, Ochoa JP, Peichl P, Pereira AC, Schwartz PJ, Skinner J, Stellbrink C, Tfelt-Hansen J, and Deneke T
- Subjects
- Asia, Consensus, Genetic Testing, Humans, Latin America, Atrial Fibrillation
- Published
- 2022
- Full Text
- View/download PDF
13. Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis.
- Author
-
Mascia G, Crotti L, Groppelli A, Canepa M, Merlo AC, Benenati S, Di Donna P, Della Bona R, Soranna D, Zambon A, Porto I, Olivotto I, Parati G, Brignole M, and Cecchi F
- Subjects
- Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac etiology, Humans, Risk Assessment methods, Risk Factors, Syncope complications, Syncope diagnosis, Syncope epidemiology, Cardiomyopathy, Hypertrophic complications, Cardiomyopathy, Hypertrophic diagnosis, Cardiomyopathy, Hypertrophic epidemiology
- Abstract
Aims: To describe the proportion of patients with syncope among those affected by hypertrophic cardiomyopathy (HCM) and the relevance of syncope as risk factor for sudden cardiac death and life-threatening arrhythmic events., Method and Results: Systematic review of original articles that assessed syncope in HCM patients. Literature search of PubMed including all English publications from 1973 to 2021.We found 57 articles for a total of 21.791 patients; of these, 14 studies reported on arrhythmic events in the follow-up. Syncope was reported in 15.8% (3.452 of 21.791) patients. It was considered unexplained in 91% of cases. Life-threatening arrhythmic events occurred in 3.6% of non-syncopal patients and in 7.7% of syncopal patients during a mean follow-up of 5.6 years. A relative risk of 1.99 (95%CI 1.39 to 2.86) was estimated for syncope patients by the random effect model using Haldane continuity correction for 0 events., Conclusions: In the current practice, the cause of syncope remained unexplained in most patients affected by HCM. The management of patients seems mainly driven by risk stratification rather than identification of the aetiology of syncope. There is a need of precise instructions how to apply the recommendations of current guidelines to this disease, which tests are indicated and how to interpret their findings. The protocol was registered in Prospero (ID: 275963)., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
14. Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls.
- Author
-
Walsh R, Lahrouchi N, Tadros R, Kyndt F, Glinge C, Postema PG, Amin AS, Nannenberg EA, Ware JS, Whiffin N, Mazzarotto F, Škorić-Milosavljević D, Krijger C, Arbelo E, Babuty D, Barajas-Martinez H, Beckmann BM, Bézieau S, Bos JM, Breckpot J, Campuzano O, Castelletti S, Celen C, Clauss S, Corveleyn A, Crotti L, Dagradi F, de Asmundis C, Denjoy I, Dittmann S, Ellinor PT, Ortuño CG, Giustetto C, Gourraud JB, Hazeki D, Horie M, Ishikawa T, Itoh H, Kaneko Y, Kanters JK, Kimoto H, Kotta MC, Krapels IPC, Kurabayashi M, Lazarte J, Leenhardt A, Loeys BL, Lundin C, Makiyama T, Mansourati J, Martins RP, Mazzanti A, Mörner S, Napolitano C, Ohkubo K, Papadakis M, Rudic B, Molina MS, Sacher F, Sahin H, Sarquella-Brugada G, Sebastiano R, Sharma S, Sheppard MN, Shimamoto K, Shoemaker MB, Stallmeyer B, Steinfurt J, Tanaka Y, Tester DJ, Usuda K, van der Zwaag PA, Van Dooren S, Van Laer L, Winbo A, Winkel BG, Yamagata K, Zumhagen S, Volders PGA, Lubitz SA, Antzelevitch C, Platonov PG, Odening KE, Roden DM, Roberts JD, Skinner JR, Tfelt-Hansen J, van den Berg MP, Olesen MS, Lambiase PD, Borggrefe M, Hayashi K, Rydberg A, Nakajima T, Yoshinaga M, Saenen JB, Kääb S, Brugada P, Robyns T, Giachino DF, Ackerman MJ, Brugada R, Brugada J, Gimeno JR, Hasdemir C, Guicheney P, Priori SG, Schulze-Bahr E, Makita N, Schwartz PJ, Shimizu W, Aiba T, Schott JJ, Redon R, Ohno S, Probst V, Behr ER, Barc J, and Bezzina CR
- Subjects
- Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac genetics, Genetic Testing, Humans, Mutation, Population Control, Brugada Syndrome genetics, Long QT Syndrome diagnosis, Long QT Syndrome epidemiology, Long QT Syndrome genetics
- Abstract
Purpose: Stringent variant interpretation guidelines can lead to high rates of variants of uncertain significance (VUS) for genetically heterogeneous disease like long QT syndrome (LQTS) and Brugada syndrome (BrS). Quantitative and disease-specific customization of American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines can address this false negative rate., Methods: We compared rare variant frequencies from 1847 LQTS (KCNQ1/KCNH2/SCN5A) and 3335 BrS (SCN5A) cases from the International LQTS/BrS Genetics Consortia to population-specific gnomAD data and developed disease-specific criteria for ACMG/AMP evidence classes-rarity (PM2/BS1 rules) and case enrichment of individual (PS4) and domain-specific (PM1) variants., Results: Rare SCN5A variant prevalence differed between European (20.8%) and Japanese (8.9%) BrS patients (p = 5.7 × 10
-18 ) and diagnosis with spontaneous (28.7%) versus induced (15.8%) Brugada type 1 electrocardiogram (ECG) (p = 1.3 × 10-13 ). Ion channel transmembrane regions and specific N-terminus (KCNH2) and C-terminus (KCNQ1/KCNH2) domains were characterized by high enrichment of case variants and >95% probability of pathogenicity. Applying the customized rules, 17.4% of European BrS and 74.8% of European LQTS cases had (likely) pathogenic variants, compared with estimated diagnostic yields (case excess over gnomAD) of 19.2%/82.1%, reducing VUS prevalence to close to background rare variant frequency., Conclusion: Large case-control data sets enable quantitative implementation of ACMG/AMP guidelines and increased sensitivity for inherited arrhythmia genetic testing.- Published
- 2021
- Full Text
- View/download PDF
15. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.
- Author
-
Crotti L and Arbelo E
- Subjects
- Arrhythmias, Cardiac, Betacoronavirus, COVID-19, Electrocardiography, Humans, Registries, SARS-CoV-2, COVID-19 Drug Treatment, Coronavirus, Coronavirus Infections drug therapy, Pandemics, Pneumonia, Viral
- Published
- 2020
- Full Text
- View/download PDF
16. Risk factors for primary ventricular fibrillation during a first myocardial infarction: Clinical findings from PREDESTINATION (PRimary vEntricular fibrillation and suDden dEath during firST myocardIal iNfArcTION).
- Author
-
De Ferrari GM, Dusi V, Ruffinazzi M, Masiello LC, Ruffino E, Cacciavillani L, Noussan P, Zacà V, Sanna T, Lazzarotti ML, Usmiani T, Gnecchi M, Parati G, Crotti L, and Schwartz PJ
- Subjects
- Atrial Fibrillation epidemiology, Case-Control Studies, Female, Humans, Incidence, Italy epidemiology, Male, Middle Aged, Myocardial Infarction mortality, Risk Factors, Survival Rate trends, Ventricular Fibrillation mortality, Atrial Fibrillation etiology, Death, Sudden, Cardiac epidemiology, Myocardial Infarction complications, Ventricular Fibrillation etiology
- Abstract
Background: Few studies prospectively assessed risk factors for ventricular fibrillation (VF) during a first myocardial infarction (MI). We designed a nation-wide study aiming to identify clinical and genetic characteristics associated with primary VF; and report here about clinical features., Methods: PREDESTINATION (PRimary vEntricular fibrillation and suDden dEath during a firST myocardIal iNfArcTION) is an Italian case-control, prospective multicentre study. Cases are patients aged 18-80 years with a first MI and at least one VF episodes occurring within 24 h of symptoms onset, before reperfusion. Cases and controls are paired 1: 2 by gender and age (±5 years)., Results: Among 1026 patients enrolled between 2007 and 2017, 970 entered the primary analysis: 375 cases and 595 controls (mean age 59 years, 85% males). Multivariable analysis identified 5 independent predictors of primary VF: systolic blood pressure (OR 0.982, 95% CI: 0.98-0.99 for each mm Hg) and K
+ levels <3.5 mEq/L at presentation (OR 2.28, 95% CI: 1.6-3.3), family history of sudden death (OR 1.80, 95% CI: 1.1-3.0), physical inactivity (OR 1.73, 95% CI: 1.1-2.8) and anterior MI (OR 1.52, 95% CI: 1.1-2.1). Excluding K+ levels obtained after VF, the OR associated with K+ levels <3.5 mEq/L was1.99 (95 CI 1.22-3.21)., Conclusions: The present study identified 5 independent predictors of primary VF: familiarity, anterior MI, low systolic blood pressure, physical inactivity and hypokalaemia. Importantly, the last two risk factors are modifiable and, especially in the presence of a family history of sudden death, they should be avoided as much as possible., (Copyright © 2019. Published by Elsevier B.V.)- Published
- 2020
- Full Text
- View/download PDF
17. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy.
- Author
-
Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, Torchio M, Marceca A, Meda M, Gasparini M, Boschi B, Girolami F, Parati G, Olivotto I, Crotti L, and Cecchi F
- Subjects
- Adult, Aged, Amyloidosis therapy, Cardiomyopathy, Hypertrophic therapy, Cohort Studies, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Prevalence, Amyloidosis diagnostic imaging, Amyloidosis epidemiology, Cardiomyopathy, Hypertrophic diagnostic imaging, Cardiomyopathy, Hypertrophic epidemiology, Referral and Consultation trends, Tertiary Care Centers trends
- Abstract
Background: Differential diagnosis of genetic causes of left ventricular hypertrophy (LVH) is crucial for disease-specific therapy. We aim to describe the prevalence of Cardiac Amyloidosis (CA) among patients ≥40 years with an initial diagnosis of HCM referred for second opinion to national cardiomyopathy centres., Methods: Consecutive patients aged ≥40 years referred with a tentative HCM diagnosis in the period 2014-2017 underwent clinical evaluation and genetic testing for HCM (including trans-thyretin-TTR). Patients with at least one red flag for CA underwent blood/urine tests, abdominal fat biopsy and/or bone-scintigraphy tracing and eventually ApoAI sequencing., Results: Out of 343 patients (age 60 ± 13 years), 251 (73%) carried a likely/pathogenic gene variant, including 12 (3.5%) in the CA-associated genes TTR (n = 11) and ApoAI (n = 1). Furthermore, 6 (2%) patients had a mutation in GLA. Among the remaining, mutation-negative patients, 26 with ≥1 CA red-flag were investigated further: 3 AL-CA and 17 wild-type-TTR-CA were identified. Ultimately, 32(9%) patients were diagnosed with CA. Prevalence of CA increased with age: 1/75 (1%) at age 40-49, 2/86 (2%) at age 50-59, 8/84 (9%) at age 60-69, 13/61 (21%) at age 70-79, 8/31 (26%) at age ≥80 (p for trend <0.01)., Conclusions: Among patients referred with and initial diagnosis of HCM, CA was the most common unrecognized mimic (9% prevalence) and increased with age (from 1% at ages 40-49 years to 26% >80 years). Age at diagnosis should be considered one of the most relevant red flags for CA in patients with HCM phenotypes; however, there is no clear age cut-off mandating scintigraphy and other second level investigations in the absence of other features suggestive of CA., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1.
- Author
-
Mura M, Bastaroli F, Corli M, Ginevrino M, Calabrò F, Boni M, Crotti L, Valente EM, Schwartz PJ, and Gnecchi M
- Subjects
- Adult, Cell Differentiation, Cell Line, Female, Humans, Kruppel-Like Factor 4, Induced Pluripotent Stem Cells metabolism, Long QT Syndrome genetics
- Abstract
We generated human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a 40 years old female patient homozygous for the mutation c.535 G > A p.G179S on the KCNQ1 gene, causing a severe form of autosomal recessive Long QT Syndrome type 1 (AR-LQT1). The hiPSCs, generated using classical approach of the four retroviruses enconding the reprogramming factors OCT4, SOX2, cMYC and KLF4, display pluripotent stem cell characteristics, and differentiate into cell lineages of all three germ layers: endoderm, mesoderm and ectoderm., Competing Interests: Declaration of Competing Interest None., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
19. Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population.
- Author
-
Mura M, Pisano F, Stefanello M, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Brink PA, and Gnecchi M
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing metabolism, Heart Arrest genetics, Heart Arrest metabolism, Humans, Immunohistochemistry, Karyotyping, Mutation genetics, Reverse Transcriptase Polymerase Chain Reaction, Skin cytology, South Africa, Induced Pluripotent Stem Cells cytology, Induced Pluripotent Stem Cells metabolism, Long QT Syndrome metabolism
- Abstract
We generated PSMi001-A and PSMi008-A hiPSC lines from two individuals belonging to a South African (SA) founder population in which the malignant KCNQ1-A341V mutation cosegregates with the Long QT Syndrome (LQTS) phenotype. PSMi001-A was derived from an asymptomatic KCNQ1-A341V mutation carrier, whereas PSMi008-A was derived from a healthy non-mutation carrier, heterozygous for the minor variant rs16847548 on the NOS1AP gene, associated with QT prolongation in the general population, and with a greater risk for cardiac arrest in the affected members of the SA founder population. The hiPSCs, generated using the Yamanaka's retroviruses, display pluripotent stem cell features and trilineage differentiation potential., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
20. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation.
- Author
-
Mura M, Lee YK, Pisano F, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Tse HF, and Gnecchi M
- Subjects
- Adult, Cells, Cultured, Female, Fibroblasts metabolism, Heterozygote, Humans, Induced Pluripotent Stem Cells metabolism, Kruppel-Like Factor 4, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Phenotype, Romano-Ward Syndrome pathology, Cell Differentiation, Cellular Reprogramming, Fibroblasts pathology, Induced Pluripotent Stem Cells pathology, KCNQ1 Potassium Channel genetics, Mutation, Romano-Ward Syndrome genetics
- Abstract
We generated human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a woman carrier of the heterozygous mutation c.568C > T p.R190W on the KCNQ1 gene. hiPSCs, obtained using four retroviruses enconding the reprogramming factors OCT4, SOX2, cMYC and KLF4, display pluripotent stem cell characteristics, and can be differentiated into spontaneously beating cardiomyocytes (hiPSC-CMs)., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
21. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation.
- Author
-
Mura M, Lee YK, Pisano F, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Tse HF, and Gnecchi M
- Subjects
- Adult, Cells, Cultured, Cellular Reprogramming, Fibroblasts metabolism, Humans, Induced Pluripotent Stem Cells metabolism, Kruppel-Like Factor 4, Male, Myocytes, Cardiac metabolism, Phenotype, Romano-Ward Syndrome pathology, Cell Differentiation, Fibroblasts pathology, Induced Pluripotent Stem Cells pathology, KCNQ1 Potassium Channel genetics, Mutation, Myocytes, Cardiac pathology, Romano-Ward Syndrome genetics
- Abstract
We generated human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a male carrier of the heterozygous mutation c.1781 G > A p.R594Q on the KCNQ1 gene. hiPSCs, generated using four retroviruses each encoding for OCT4, SOX2, KLF4 and cMYC, display pluripotent stem cell characteristics, and can be differentiated into spontaneously beating cardiomyocytes (hiPSC-CMs)., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
22. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene.
- Author
-
Mura M, Pisano F, Stefanello M, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Brink PA, and Gnecchi M
- Subjects
- Cell Differentiation, Cellular Reprogramming Techniques, DNA Mutational Analysis, Female, Heterozygote, Homozygote, Humans, Karyotype, Kruppel-Like Factor 4, Middle Aged, Adaptor Proteins, Signal Transducing genetics, Cell Line, Induced Pluripotent Stem Cells, KCNQ1 Potassium Channel genetics, Romano-Ward Syndrome genetics
- Abstract
We generated human induced pluripotent stem cells (hiPSCs) from a symptomatic Long QT Syndrome (LQTS) type 1 patient, belonging to a South African (SA) founder population segregating the heterozygous mutation c.1022C > T p.A341V on the KCNQ1 gene. The patient is also homozygous for the two minor variants rs4657139 and rs16847548 on the NOS1AP gene, associated with greater risk for cardiac arrest and sudden death in LQTS mutation carriers of the founder population. hiPSCs, obtained using four retroviruses encoding the reprogramming factors OCT4, SOX2, cMYC and KLF4, display pluripotent stem cell characteristics, and can be differentiated into spontaneously beating cardiomyocytes (hiPSC-CMs)., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
23. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene.
- Author
-
Mura M, Lee YK, Ginevrino M, Zappatore R, Pisano F, Boni M, Dagradi F, Crotti L, Valente EM, Schwartz PJ, Tse HF, and Gnecchi M
- Subjects
- Amino Acid Substitution, Cell Line, Child, Female, Humans, Kruppel-Like Factor 4, Heterozygote, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells pathology, Jervell-Lange Nielsen Syndrome genetics, Jervell-Lange Nielsen Syndrome metabolism, Jervell-Lange Nielsen Syndrome pathology, KCNQ1 Potassium Channel genetics, Mutation, Missense
- Abstract
We report the generation of human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a female patient carrier of the two compound heterozygous mutations c.568 C>T p.R190W (maternal allele), and c.1781 G>A p.R594Q (paternal allele) on the KCNQ1 gene, causing Jervell and Lange-Nielsen Syndrome (JLNS). To obtain hiPSCs, we used the classical approach of the four retroviruses each encoding for a reprogramming factor OCT4, SOX2, KLF4, cMYC. The obtained hiPSC clones display pluripotent stem cell characteristics, and differentiate into spontaneously beating cardiomyocytes (hiPSC-CMs)., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
24. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1.
- Author
-
Mura M, Ginevrino M, Zappatore R, Pisano F, Boni M, Castelletti S, Crotti L, Valente EM, Schwartz PJ, and Gnecchi M
- Subjects
- Cell Line, Female, Humans, Kruppel-Like Factor 4, Middle Aged, Transcription Factors biosynthesis, Transcription Factors genetics, Cellular Reprogramming Techniques, Genes, Recessive, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells pathology, Romano-Ward Syndrome genetics, Romano-Ward Syndrome metabolism, Romano-Ward Syndrome pathology
- Abstract
We generated human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a 51years old female patient homozygous for the mutation c.535 G>A p.G179S on the KCNQ1 gene, causing a severe form of autosomal recessive Long QT Syndrome type 1 (AR-LQT1), not associated with deafness. The hiPSCs, generated using four retroviruses each encoding for a reprogramming factor OCT4, SOX2, KLF4, cMYC, are pluripotent and can differentiate into spontaneously beating cardiomyocytes (hiPSC-CMs)., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
25. Common presentation of rare cardiac diseases: Arrhythmias.
- Author
-
Olivotto I, Finocchiaro G, Maurizi N, and Crotti L
- Subjects
- Arrhythmias, Cardiac genetics, Atrial Fibrillation diagnosis, Atrial Fibrillation genetics, Atrial Fibrillation physiopathology, Cardiomyopathies diagnosis, Cardiomyopathies genetics, Cardiomyopathies physiopathology, Electrocardiography methods, Heart Diseases diagnosis, Heart Diseases genetics, Heart Diseases physiopathology, Humans, Rare Diseases genetics, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac physiopathology, Rare Diseases diagnosis, Rare Diseases physiopathology
- Abstract
Ventricular or supraventricular ectopic beats or atrial fibrillation may be the first presentation of uncommon cardiac disease, both acquired and genetically determined. In some patients, these manifestations can be the first sign of the underlying cardiac disorder. In others, however, they are also important as prognostic indicators, reflecting electrical instability and risk. Most cardiology clinics are busy environments where the implementation of complex diagnostic algorithms is not feasible. However, it is equally impossible to reach a final diagnosis, among the thousands of rare diseases that involve the heart, moving from a first line clinical and instrumental examination. Cardiac and extra-cardiac red flags, an accurate family and clinical history and ECG interpretation may be of help in identifying a rare disease. Advanced imaging and laboratory testing at experienced referral centers is then necessary to reach a final diagnosis, but the first step in the right direction, based on these simple elements, is the most important. We here review arrhythmic presentations of rare or relatively rare diseases, and suggest a simple "rule out-rule in" approach to help direct clinical suspicion and minimize risk of neglect., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
26. The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?
- Author
-
Leinonen JT, Crotti L, Djupsjöbacka A, Castelletti S, Junna N, Ghidoni A, Tuiskula AM, Spazzolini C, Dagradi F, Viitasalo M, Kontula K, Kotta MC, Widén E, Swan H, and Schwartz PJ
- Subjects
- Adolescent, Adult, Child, Cohort Studies, Female, Finland epidemiology, Humans, Italy epidemiology, Male, Middle Aged, Mutation genetics, Sequence Analysis, DNA methods, Tachycardia, Ventricular diagnosis, Ventricular Fibrillation diagnosis, Young Adult, Genetic Variation genetics, Tachycardia, Ventricular epidemiology, Tachycardia, Ventricular genetics, Ventricular Fibrillation epidemiology, Ventricular Fibrillation genetics
- Abstract
Background: Ventricular fibrillation (VF) is a major cause of sudden cardiac death. In some cases clinical investigations fail to identify the underlying cause and the event is classified as idiopathic (IVF). Since mutations in arrhythmia-associated genes frequently determine arrhythmia susceptibility, screening for disease-predisposing variants could improve IVF diagnostics., Methods and Results: The study included 76 Finnish and Italian patients with a mean age of 31.2years at the time of the VF event, collected between the years 1996-2016 and diagnosed with idiopathic, out-of-hospital VF. Using whole-exome sequencing (WES) and next-generation sequencing (NGS) approaches, we aimed to identify genetic variants potentially contributing to the life-threatening arrhythmias of these patients. Combining the results from the two study populations, we identified pathogenic or likely pathogenic variants residing in the RYR2, CACNA1C and DSP genes in 7 patients (9%). Most of them (5, 71%) were found in the RYR2 gene, associated with catecholaminergic polymorphic ventricular tachycardia (CPVT). These genetic findings prompted clinical investigations leading to disease reclassification. Additionally, in 9 patients (11.8%) we detected 10 novel or extremely rare (MAF<0.005%) variants that were classified as of unknown significance (VUS)., Conclusion: The results of our study suggest that a subset of patients originally diagnosed with IVF may carry clinically-relevant variants in genes associated with cardiac channelopathies and cardiomyopathies. Although misclassification of other cardiac channelopathies as IVF appears rare, our findings indicate that the possibility of CPVT as the underlying disease entity should be carefully evaluated in IVF patients., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
27. Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation.
- Author
-
Castelletti S, Vischer AS, Syrris P, Crotti L, Spazzolini C, Ghidoni A, Parati G, Jenkins S, Kotta MC, McKenna WJ, Schwartz PJ, and Pantazis A
- Subjects
- Adult, Arrhythmogenic Right Ventricular Dysplasia physiopathology, Electrocardiography trends, Female, Humans, Male, Middle Aged, Mutation genetics, Arrhythmogenic Right Ventricular Dysplasia diagnostic imaging, Arrhythmogenic Right Ventricular Dysplasia genetics, Desmoplakins genetics, Genetic Association Studies methods, Mutation, Missense genetics
- Abstract
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is traditionally considered as primarily affecting the right ventricle. Mutations in genes encoding desmosomal proteins account for 40-60% of cases. Genotype-phenotype correlations are scant and mostly non gene-specific. Accordingly, we assessed the genotype-phenotype correlation for desmoplakin (DSP) missense and non-missense mutations causing ARVC., Methods and Results: We analyzed 27 ARVC patients carrying a missense or a non-missense DSP mutation, with complete clinical assessment. The two groups were compared for clinical parameters, basic demographics such as sex, age at diagnosis, age at disease onset, as well as prevalence of symptoms and arrhythmic events. Missense DSP variants were present in 10 patients and non-missense in 17. Mean age at diagnosis and at first arrhythmic event did not differ between the two groups. Also the prevalence of symptoms, either major (60% vs 59%, p=1) or all (80% vs 88%, p=0.61), did not differ. By contrast, left ventricular (LV) dysfunction was significantly more prevalent among patients with non-missense mutations (76.5% vs 10%, p=0.001), who were also much more likely to have a structural LV involvement by Cardiac Magnetic Resonance (CMR) (92% vs 22%, p=0.001)., Conclusions: For ARVC patients, both missense and non-missense DSP mutations carry a high arrhythmic risk. Non-missense mutations are specifically associated with left-dominant forms. The presence of DSP non-missense mutations should alert to the likely development of LV dysfunction. These findings highlight the clinical relevance of genetic testing even after the clinical diagnosis of ARVC and the growing clinical impact of genetics., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
28. Founder populations with channelopathies and church records reveal all sorts of interesting secrets: Some are scientifically relevant.
- Author
-
Schwartz PJ and Crotti L
- Subjects
- Humans, Channelopathies
- Published
- 2017
- Full Text
- View/download PDF
29. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2.
- Author
-
Mura M, Mehta A, Ramachandra CJ, Zappatore R, Pisano F, Ciuffreda MC, Barbaccia V, Crotti L, Schwartz PJ, Shim W, and Gnecchi M
- Subjects
- Female, Gene Expression, Humans, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells pathology, Long QT Syndrome pathology, Male, Myocytes, Cardiac pathology, Pedigree, Protein Transport physiology, ERG1 Potassium Channel biosynthesis, ERG1 Potassium Channel genetics, Long QT Syndrome genetics, Long QT Syndrome metabolism, Mutation genetics, Myocytes, Cardiac metabolism
- Abstract
Background: Long QT Syndrome type 2 (LQT2) is caused by mutations in the KCNH2 gene that encodes for the α-subunit (hERG) of the ion channel conducting the rapid delayed rectifier potassium current (I
Kr ). We have previously identified a disease causing mutation (IVS9-28A/G) in the branch point of the splicing of KCNH2 intron 9. However, the mechanism through which this mutation causes the disease is unknown., Methods and Results: We generated human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from fibroblasts of two IVS9-28A/G mutation carriers. IVS9-28A/G iPSC-CMs showed prolonged repolarization time, mimicking what observed at the ECG level in the same patients. The expression of the full-length ERG1a isoform resulted reduced, whereas the C-terminally truncated ERG1aUSO isoform was upregulated in mutant iPSC-CMs, with consequent alteration of the physiological ERG1aUSO /ERG1a ratio. Importantly, we observed an impairment of hERG trafficking to the cell membrane. The severity of the alterations in hERG expression and trafficking correlated with the clinical severity of the disease in the two patients under study. Finally, we were able to revert the trafficking defect and reduce the repolarization duration in LQT2 iPSC-CMs using the proteasome inhibitor ALLN., Conclusion: Our results highlight the key role of the KCNH2 intron 9 branch point in the regulation of KCNH2 isoform expression and hERG channel function, and allow to categorize the IVS9-28A/G mutation as LQT2 class 2 mutation. These findings may result in a more personalized clinical management of IVS9-28A/G mutation carriers., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
30. The role of genetics in primary ventricular fibrillation, inherited channelopathies and cardiomyopathies.
- Author
-
Crotti L and Kotta MC
- Subjects
- Cardiomyopathies diagnosis, Cardiomyopathies prevention & control, Channelopathies diagnosis, Channelopathies prevention & control, Humans, Ventricular Fibrillation diagnosis, Ventricular Fibrillation prevention & control, Cardiomyopathies genetics, Channelopathies genetics, Death, Sudden, Cardiac prevention & control, Genetic Predisposition to Disease genetics, Genetic Testing trends, Ventricular Fibrillation genetics
- Abstract
Sudden cardiac death (SCD) has a strong familial component; however, our understanding of its genetic basis varies significantly according to the underlying causes. When coronary artery disease is involved, the predisposing genetic background is complex and despite some interesting findings it remains largely unknown. Quite different is the case of monogenic structural and non-structural heart diseases, in which a number of disease-causing genes have been established and are being used in clinical practice. As SCD can be the first clinical manifestation of inherited syndromes, in order to ascertain the cause of death, it is extremely important to include molecular autopsy among the standard post-mortem examinations. Indeed, molecular screening of the major disease-causing genes in the deceased person is often the only way to achieve a post-mortem diagnosis in channelopathies, which may prove crucial for the identification and management of at risk family members. Overall, these data, together with the inclusion in current guidelines of molecular screening for diagnosis and/or risk stratification of specific inherited cardiac diseases, exemplify how research on the genetic basis of SCD may be deeply translational, while the transition of genetic testing from the research to the diagnostic setting is already improving every-day clinical practice., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
31. Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes.
- Author
-
Pipilas DC, Johnson CN, Webster G, Schlaepfer J, Fellmann F, Sekarski N, Wren LM, Ogorodnik KV, Chazin DM, Chazin WJ, Crotti L, Bhuiyan ZA, and George AL Jr
- Subjects
- Action Potentials physiology, Calmodulin metabolism, Child, Preschool, Electrocardiography methods, Genetic Predisposition to Disease, Humans, Infant, Male, Mutation, Myocytes, Cardiac metabolism, Switzerland, Calmodulin genetics, Long QT Syndrome diagnosis, Long QT Syndrome genetics, Long QT Syndrome physiopathology
- Abstract
Background: Calmodulin (CaM) mutations are associated with cardiac arrhythmia susceptibility including congenital long QT syndrome (LQTS)., Objective: The purpose of this study was to determine the clinical, genetic, and functional features of 2 novel CaM mutations in children with life-threatening ventricular arrhythmias., Methods: The clinical and genetic features of 2 congenital arrhythmia cases associated with 2 novel CaM gene mutations were ascertained. Biochemical and functional investigations were conducted on the 2 mutations., Results: A novel de novo CALM2 mutation (D132H) was discovered by candidate gene screening in a male infant with prenatal bradycardia born to healthy parents. Postnatal course was complicated by profound bradycardia, prolonged corrected QT interval (651 ms), 2:1 atrioventricular block, and cardiogenic shock. He was resuscitated and was treated with a cardiac device. A second novel de novo mutation in CALM1 (D132V) was discovered by clinical exome sequencing in a 3-year-old boy who suffered a witnessed cardiac arrest secondary to ventricular fibrillation. Electrocardiographic recording after successful resuscitation revealed a prolonged corrected QT interval of 574 ms. The Ca(2+) affinity of CaM-D132H and CaM-D132V revealed extremely weak binding to the C-terminal domain, with significant structural perturbations noted for D132H. Voltage-clamp recordings of human induced pluripotent stem cell-derived cardiomyocytes transiently expressing wild-type or mutant CaM demonstrated that both mutations caused impaired Ca(2+)-dependent inactivation of voltage-gated Ca(2+) current. Neither mutant affected voltage-dependent inactivation., Conclusion: Our findings implicate impaired Ca(2+)-dependent inactivation in human cardiomyocytes as the plausible mechanism for long QT syndrome associated with 2 novel CaM mutations. The data further expand the spectrum of genotype and phenotype associated with calmodulinopathy., (Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
32. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome.
- Author
-
Andorin A, Behr ER, Denjoy I, Crotti L, Dagradi F, Jesel L, Sacher F, Petit B, Mabo P, Maltret A, Wong LC, Degand B, Bertaux G, Maury P, Dulac Y, Delasalle B, Gourraud JB, Babuty D, Blom NA, Schwartz PJ, Wilde AA, and Probst V
- Subjects
- Adolescent, Asymptomatic Diseases epidemiology, Child, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Electrocardiography methods, Female, Humans, Male, Prognosis, Risk Assessment, Syncope etiology, Syncope prevention & control, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular etiology, Tachycardia, Ventricular prevention & control, Brugada Syndrome diagnosis, Brugada Syndrome genetics, Brugada Syndrome physiopathology, Brugada Syndrome therapy, Electric Countershock instrumentation, Electric Countershock methods, NAV1.5 Voltage-Gated Sodium Channel genetics
- Abstract
Background: Brugada syndrome (BrS) is an arrhythmogenic disease associated with sudden cardiac death (SCD) that seldom manifests or is recognized in childhood., Objectives: The objectives of this study were to describe the clinical presentation of pediatric BrS to identify prognostic factors for risk stratification and to propose a data-based approach management., Methods: We studied 106 patients younger than 19 years at diagnosis of BrS enrolled from 16 European hospitals., Results: At diagnosis, BrS was spontaneous (n = 36, 34%) or drug-induced (n = 70, 66%). The mean age was 11.1 ± 5.7 years, and most patients were asymptomatic (family screening, (n = 67, 63%; incidental, n = 13, 12%), while 15 (14%) experienced syncope, 6(6%) aborted SCD or symptomatic ventricular tachycardia, and 5 (5%) other symptoms. During follow-up (median 54 months), 10 (9%) patients had life-threatening arrhythmias (LTA), including 3 (3%) deaths. Six (6%) experienced syncope and 4 (4%) supraventricular tachycardia. Fever triggered 27% of LTA events. An implantable cardioverter-defibrillator was implanted in 22 (21%), with major adverse events in 41%. Of the 11 (10%) patients treated with hydroquinidine, 8 remained asymptomatic. Genetic testing was performed in 75 (71%) patients, and SCN5A rare variants were identified in 58 (55%); 15 of 32 tested probands (47%) were genotype positive. Nine of 10 patients with LTA underwent genetic testing, and all were genotype positive, whereas the 17 SCN5A-negative patients remained asymptomatic. Spontaneous Brugada type 1 electrocardiographic (ECG) pattern (P = .005) and symptoms at diagnosis (P = .001) were predictors of LTA. Time to the first LTA event was shorter in patients with both symptoms at diagnosis and spontaneous Brugada type 1 ECG pattern (P = .006)., Conclusion: Spontaneous Brugada type 1 ECG pattern and symptoms at diagnosis are predictors of LTA events in the young affected by BrS. The management of BrS should become age-specific, and prevention of SCD may involve genetic testing and aggressive use of antipyretics and quinidine, with risk-specific consideration for the implantable cardioverter-defibrillator., (Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
33. A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: validation of the 2013 diagnostic criteria.
- Author
-
Savastano S, Rordorf R, Vicentini A, Petracci B, Taravelli E, Castelletti S, D'Errico A, Torchio M, Dossena C, Novara P, Dagradi F, Landolina M, Spazzolini C, Crotti L, and Schwartz PJ
- Subjects
- Adult, Brugada Syndrome genetics, Brugada Syndrome physiopathology, Female, Genetic Predisposition to Disease, Humans, Italy, Male, Middle Aged, Mutation, NAV1.5 Voltage-Gated Sodium Channel genetics, Brugada Syndrome diagnosis, Echocardiography methods, Electrocardiography methods
- Abstract
Background: The debate on the diagnostic value of high intercostal spaces (ICSs) and of the number of diagnostic leads in Brugada syndrome (BrS) has been settled by a recent expert consensus statement., Objective: To test the validity, and the underlying anatomy, of the new electrocardiographic (ECG) diagnostic criteria using echocardiographic, molecular, and clinical evidence in 1 clinical study population with BrS., Methods: We analyzed 114 patients with BrS and with a spontaneous or drug-induced type 1 ECG pattern recorded in 1 or more right precordial leads in fourth, third, and second ICSs. The right ventricular outflow tract (RVOT) was localized by using echocardiography. All probands were screened on the SCN5A gene., Results: The percentage of mutation carriers (MCs) and the event rate were similar regardless of the diagnostic ICS (fourth vs high ICSs: MCs 23% vs 19%; event rate 22% vs 28%) and the number of diagnostic leads (1 vs ≥2: MCs 20% vs 22%; event rate 22% vs 27%). The concordance between RVOT anatomical location and the diagnostic ICSs was 86%. The percentage of the diagnostic ECG pattern recorded was significantly increased by the exploration of the ICSs showing RVOT by echocardiography (echocardiography-guided approach vs conventional approach 100% vs 43%; P < .001)., Conclusion: The high ICSs are not inferior to the standard fourth ICS for the ECG diagnosis of BrS, and the interindividual variability depends on the anatomical location of the RVOT as assessed by using echocardiography. This approach significantly increases diagnostic sensitivity without decreasing specificity and fully supports the recently published new diagnostic criteria., (Copyright © 2014 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
34. Reply to the Editor--Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.
- Author
-
Schwartz PJ and Crotti L
- Subjects
- Animals, Humans, Death, Sudden, Cardiac prevention & control, Electrocardiography drug effects, Long QT Syndrome drug therapy, Propranolol administration & dosage
- Published
- 2014
- Full Text
- View/download PDF
35. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.
- Author
-
Calvillo L, Spazzolini C, Vullo E, Insolia R, Crotti L, and Schwartz PJ
- Subjects
- Adrenergic beta-Antagonists administration & dosage, Animals, Cardiac Conduction System Disease, Death, Sudden, Cardiac etiology, Disease Models, Animal, Heart Conduction System drug effects, Heart Conduction System physiopathology, Humans, Injections, Intraperitoneal, Long QT Syndrome complications, Long QT Syndrome physiopathology, Mice, Mice, Transgenic, Treatment Outcome, Death, Sudden, Cardiac prevention & control, Electrocardiography drug effects, Long QT Syndrome drug therapy, Propranolol administration & dosage
- Abstract
Background: The efficacy of beta-blockers for treatment of patients with long QT syndrome type 3 (LQT3) has been repeatedly questioned, and it has been suggested that they might be detrimental for this genetic subgroup of patients with long QT syndrome (LQTS). The disquieting consequence has been that cardiologists confronted with LQT3 patients often do not even attempt pharmacologic therapy and implant cardioverter-defibrillators as first-choice treatment. However, the most recent clinical data indicate high efficacy of beta-blocker therapy in LQT3 patients., Objective: The purpose of this study was to test the antiarrhythmic efficacy of beta-blockers in an established experimental model for LQT3., Methods: After phenotypic validation of 65 ∆KPQ-SCN5A knock-in transgenic (TG) mice compared to 32 wild-type (WT) mice, we tested the effect of the arrhythmogenic cholinergic muscarinic agonist carbachol in 19 WT and 39 TG anesthetized mice, with and without pretreatment with propranolol given intraperitoneally., Results: At the same heart rates, TG mice had a markedly longer QT interval than WT mice. Whereas carbachol had minor arrhythmic effects in the WT mice, it produced ventricular tachycardia (VT) and ventricular fibrillation (VF) in 55% of 20 TG mice. By contrast, in none of 19 TG mice pretreated with propranolol did VT/VF occur after carbachol injection., Conclusion: These experimental data indicate that, contrary to previous reports, beta-blockade effectively prevents VT/VF in a validated LQT3 model. Together with the most recent clinical data, these findings indicate that there is no reason for not initiating protective therapy with beta-blockers in LQT3 patients., (© 2013 Heart Rhythm Society Published by Heart Rhythm Society All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
36. FGF12 is a candidate Brugada syndrome locus.
- Author
-
Hennessey JA, Marcou CA, Wang C, Wei EQ, Wang C, Tester DJ, Torchio M, Dagradi F, Crotti L, Schwartz PJ, Ackerman MJ, and Pitt GS
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Brugada Syndrome metabolism, Brugada Syndrome pathology, Cells, Cultured, Child, Chromatography, High Pressure Liquid, DNA Mutational Analysis, Disease Models, Animal, Electrocardiography, Female, Fibroblast Growth Factors metabolism, Humans, Immunohistochemistry, Male, Middle Aged, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Phenotype, Rats, Rats, Sprague-Dawley, Young Adult, Brugada Syndrome genetics, DNA genetics, Fibroblast Growth Factors genetics, Mutation, Missense
- Abstract
Background: Less than 30% of the cases of Brugada syndrome (BrS) have an identified genetic cause. Of the known BrS-susceptibility genes, loss-of-function mutations in SCN5A or CACNA1C and their auxiliary subunits are most common. On the basis of the recent demonstration that fibroblast growth factor (FGF) homologous factors (FHFs; FGF11-FGF14) regulate cardiac Na(+) and Ca(2+) channel currents, we hypothesized that FHFs are candidate BrS loci., Objective: The goal of this study was to test whether FGF12 is a candidate BrS locus., Methods: We used quantitative polymerase chain reaction to identify the major FHF expressed in the human ventricle and then queried a phenotype-positive, genotype-negative BrS biorepository for FHF mutations associated with BrS. We queried the effects of an identified mutant with biochemical analyses combined with electrophysiological assessment. We designed a novel rat ventricular cardiomyocyte system in which we swapped the endogenous FHF with the identified mutant and defined its effects on multiple ionic currents in their native milieu and on the cardiac action potential., Results: We identified FGF12 as the major FHF expressed in the human ventricle. In 102 individuals in the biorepository, we identified a single missense mutation in FGF12-B (Q7R-FGF12). The mutant reduced binding to the NaV1.5 C terminus, but not to junctophilin-2. In adult rat cardiac myocytes, Q7R-FGF12, but not wild-type FGF12, reduced Na(+) channel current density and availability without affecting Ca(2+) channel function. Furthermore, the mutant, but not wild-type FGF12, reduced action potential amplitude, which is consistent with a mutant-induced loss of Na(+) channel function., Conclusions: These multilevel investigations strongly suggest that Q7R-FGF12 is a disease-associated BrS mutation. Moreover, these data suggest for the first time that FHF effects on Na(+) and Ca(2+) channels are separable. Most significantly, this study establishes a new method to analyze effects of human arrhythmogenic mutations on cardiac ionic currents., (© 2013 Heart Rhythm Society Published by Heart Rhythm Society All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
37. When genetic screening for your patient with long QT syndrome comes back negative, don't always take a no for a no.
- Author
-
Crotti L and Schwartz PJ
- Subjects
- Female, Humans, Male, DNA genetics, Genetic Predisposition to Disease, Genetic Testing methods, Long QT Syndrome diagnosis, Mutation
- Published
- 2012
- Full Text
- View/download PDF
38. Gene expression and arrhythmic risk.
- Author
-
Crotti L
- Subjects
- Female, Humans, Male, Arrhythmias, Cardiac genetics, NAV1.5 Voltage-Gated Sodium Channel genetics, Promoter Regions, Genetic genetics
- Published
- 2012
- Full Text
- View/download PDF
39. Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant.
- Author
-
Crotti L, Hu D, Barajas-Martinez H, De Ferrari GM, Oliva A, Insolia R, Pollevick GD, Dagradi F, Guerchicoff A, Greco F, Schwartz PJ, Viskin S, and Antzelevitch C
- Subjects
- Adult, Aged, Aged, 80 and over, Chromatography, High Pressure Liquid, Death, Sudden, Cardiac, ERG1 Potassium Channel, Electrocardiography, Electrophysiologic Techniques, Cardiac, Ether-A-Go-Go Potassium Channels genetics, Female, Genotyping Techniques, Heart Conduction System physiopathology, Humans, Long QT Syndrome genetics, Male, Middle Aged, Mutation, NAV1.5 Voltage-Gated Sodium Channel genetics, Polymorphism, Single Nucleotide, Myocardial Infarction complications, Myocardial Infarction genetics, Torsades de Pointes etiology, Torsades de Pointes genetics
- Abstract
Background: Although QT prolongation following myocardial infarction (MI) is generally moderate, cases with marked QT prolongation leading to life-threatening torsades de pointes (TdP) have been described., Objective: To investigate the genetic substrate of this phenomenon., Methods: We studied 13 patients who developed TdP in the subacute phase of MI (2-11 days) and a group of 133 ethnically matched controls with uncomplicated MI. Long QT syndrome genes and the KCNH2-K897T polymorphism were screened by using denaturing high-performance liquid chromatography plus direct sequencing and a specific TaqMan assay, respectively., Results: Two of the 13 patients (15%) who presented with QT prolongation and TdP were found to carry long QT syndrome mutations (KCNH2-R744X and SCN5A-E446K). Nine of the remaining 11 patients (82%) carried the KCNH2-K897T polymorphism, which was present in 35% of the controls (P = .0035). Thus, patients with an acute MI carrying the KCNH2-K897T polymorphism had an 8-fold greater risk of experiencing TdP compared with controls (95% confidence interval = 2-40)., Conclusions: Our data suggest that the common K897T polymorphism is associated with an increased risk of TdP developing in the subacute phase of MI. Our findings support the concept that the electrical remodeling associated with this healing phase of MI may unmask a genetic substrate predisposing to a time-limited development of life-threatening arrhythmias. They also provide the first line of evidence in support of the hypothesis that a common polymorphism, previously described as a modifier of the severity of LQTS, may increase the risk of life-threatening arrhythmias in a much more prevalent cardiac disease such as myocardial infarction., (Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
40. A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents.
- Author
-
Hu D, Barajas-Martínez H, Medeiros-Domingo A, Crotti L, Veltmann C, Schimpf R, Urrutia J, Alday A, Casis O, Pfeiffer R, Burashnikov E, Caceres G, Tester DJ, Wolpert C, Borggrefe M, Schwartz P, Ackerman MJ, and Antzelevitch C
- Subjects
- Adult, Arrhythmias, Cardiac metabolism, Blotting, Western, Brugada Syndrome physiopathology, Electrocardiography, Female, Genetic Predisposition to Disease, Humans, Infant, Male, Middle Aged, Molecular Biology, Mutation, Polymorphism, Genetic, Potassium Channels metabolism, Voltage-Gated Sodium Channel beta-1 Subunit metabolism, Arrhythmias, Cardiac genetics, Brugada Syndrome genetics, NAV1.5 Voltage-Gated Sodium Channel metabolism, Potassium Channels genetics, Sudden Infant Death genetics, Voltage-Gated Sodium Channel beta-1 Subunit genetics
- Abstract
Background: Cardiac sodium channel β-subunit mutations have been associated with several inherited cardiac arrhythmia syndromes., Objective: To identify and characterize variations in SCN1Bb associated with Brugada syndrome (BrS) and sudden infant death syndrome (SIDS)., Methods: All known exons and intron borders of the BrS-susceptibility genes were amplified and sequenced in both directions. Wild type (WT) and mutant genes were expressed in TSA201 cells and studied using co-immunoprecipitation and whole-cell patch-clamp techniques., Results: Patient 1 was a 44-year-old man with an ajmaline-induced type 1 ST-segment elevation in V1 and V2 supporting the diagnosis of BrS. Patient 2 was a 62-year-old woman displaying a coved-type BrS electrocardiogram who developed cardiac arrest during fever. Patient 3 was a 4-month-old female SIDS case. A R214Q variant was detected in exon 3A of SCN1Bb (Na(v)1B) in all three probands, but not in any other gene previously associated with BrS or SIDS. R214Q was identified in 4 of 807 ethnically-matched healthy controls (0.50%). Co-expression of SCN5A/WT + SCN1Bb/R214Q resulted in peak sodium channel current (I(Na)) 56.5% smaller compared to SCN5A/WT + SCN1Bb/WT (n = 11-12, P<0.05). Co-expression of KCND3/WT + SCN1Bb/R214Q induced a Kv4.3 current (transient outward potassium current, I(to)) 70.6% greater compared with KCND3/WT + SCN1Bb/WT (n = 10-11, P<0.01). Co-immunoprecipitation indicated structural association between Na(v)β1B and Na(v)1.5 and K(v)4.3., Conclusion: Our results suggest that R214Q variation in SCN1Bb is a functional polymorphism that may serve as a modifier of the substrate responsible for BrS or SIDS phenotypes via a combined loss of function of sodium channel current and gain of function of transient outward potassium current., (Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
41. Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome.
- Author
-
Giudicessi JR, Ye D, Tester DJ, Crotti L, Mugione A, Nesterenko VV, Albertson RM, Antzelevitch C, Schwartz PJ, and Ackerman MJ
- Subjects
- Action Potentials genetics, Adult, Alleles, Brugada Syndrome metabolism, Brugada Syndrome physiopathology, Cells, Cultured, Electrocardiography, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Myocardium pathology, Patch-Clamp Techniques, Polymerase Chain Reaction, Shal Potassium Channels metabolism, Young Adult, Brugada Syndrome genetics, DNA genetics, Mutation, Missense, Myocardium metabolism, Shal Potassium Channels genetics
- Abstract
Background: Brugada syndrome (BrS) is a sudden death-predisposing genetic condition characterized electrocardiographically by ST segment elevation in the leads V(1)-V(3). Given the prominent role of the transient outward current (I(to)) in BrS pathogenesis, we hypothesized that rare gain-of-function mutations in KCND3 may serve as a pathogenic substrate for BrS., Methods: Comprehensive mutational analysis of KCND3-encoded Kv4.3 (I(to)) was conducted using polymerase chain reaction, denaturing high performance liquid chromatography, and direct sequencing of DNA derived from 86 unrelated BrS1-8 genotype-negative BrS patients. DNA from 780 healthy individuals was examined to assess allelic frequency for nonsynonymous variants. Putative BrS-associated Kv4.3 mutations were engineered and coexpressed with wild-type KChIP2 in HEK293 cells. Wild-type and mutant I(to) ion currents were recorded using whole-cell patch clamp., Results: Two BrS1-8 genotype-negative cases possessed novel Kv4.3 missense mutations. Both Kv4.3-L450F and Kv4.3-G600R were absent in 1,560 reference alleles and involved residues highly conserved across species. Both Kv4.3-L450F and Kv4.3-G600R demonstrated a gain-of-function phenotype, increasing peak I(to) current density by 146.2% (n = 15, P <.05) and 50.4% (n = 15, P <.05), respectively. Simulations using a Luo-Rudy II action potential (AP) model demonstrated the stable loss of the AP dome as a result of the increased I(to) maximal conductance associated with the heterozygous expression of either L450F or G600R., Conclusions: These findings provide the first molecular and functional evidence implicating novel KCND3 gain-of-function mutations in the pathogenesis and phenotypic expression of BrS, with the potential for a lethal arrhythmia being precipitated by a genetically enhanced I(to) current gradient within the right ventricle where KCND3 expression is the highest., (Copyright © 2011. Published by Elsevier Inc.)
- Published
- 2011
- Full Text
- View/download PDF
42. Pleiotropic mutations in ion channels: what lies behind them?
- Author
-
Crotti L
- Subjects
- Atrial Fibrillation genetics, Humans, Phenotype, Polymorphism, Single Nucleotide, Genetic Pleiotropy genetics, Genetic Predisposition to Disease genetics, Mutation, Missense, Romano-Ward Syndrome genetics
- Published
- 2011
- Full Text
- View/download PDF
43. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes.
- Author
-
Medeiros-Domingo A, Tan BH, Crotti L, Tester DJ, Eckhardt L, Cuoretti A, Kroboth SL, Song C, Zhou Q, Kopp D, Schwartz PJ, Makielski JC, and Ackerman MJ
- Subjects
- Adult, Arrhythmias, Cardiac physiopathology, Brugada Syndrome physiopathology, Cells, Cultured, Chromatography, High Pressure Liquid, Computers, Handheld, DNA Mutational Analysis, Electrocardiography, Female, Genetic Predisposition to Disease genetics, Humans, KATP Channels metabolism, Male, Mutagenesis, Site-Directed, Myocardium metabolism, Sequence Analysis, DNA, Transfection, Arrhythmias, Cardiac genetics, Brugada Syndrome genetics, Mutation, Missense, Potassium Channels, Inwardly Rectifying genetics
- Abstract
Background: J-wave syndromes have emerged conceptually to encompass the pleiotropic expression of J-point abnormalities including Brugada syndrome (BrS) and early repolarization syndrome (ERS). KCNJ8, which encodes the cardiac K(ATP) Kir6.1 channel, recently has been implicated in ERS following identification of the functionally uncharacterized missense mutation S422L., Objective: The purpose of this study was to further explore KCNJ8 as a novel susceptibility gene for J-wave syndromes., Methods: Using polymerase chain reaction, denaturing high-performance liquid chromatography, and direct DNA sequencing, comprehensive open reading frame/splice site mutational analysis of KCNJ8 was performed in 101 unrelated patients with J-wave syndromes, including 87 with BrS and 14 with ERS. Six hundred healthy individuals were examined to assess the allelic frequency for all variants detected. KCNJ8 mutation(s) was engineered by site-directed mutagenesis and coexpressed heterologously with SUR2A in COS-1 cells. Ion currents were recorded using whole-cell configuration of the patch-clamp technique., Results: One BrS case and one ERS case hosted the identical missense mutation S422L, which was reported previously. KCNJ8-S422L involves a highly conserved residue and was absent in 1,200 reference alleles. Both cases were negative for mutations in all known BrS and ERS susceptibility genes. K(ATP) current of the Kir6.1-S422L mutation was increased significantly over the voltage range from 0 to 40 mV compared to Kir6.1-WT channels (n = 16-21; P <.05)., Conclusion: These findings further implicate KCNJ8 as a novel J-wave syndrome susceptibility gene and a marked gain of function in the cardiac K(ATP) Kir6.1 channel secondary to KCNJ8-S422L as a novel pathogenic mechanism for the phenotypic expression of both BrS and ERS., (Copyright © 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
44. A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome.
- Author
-
Crotti L, Lewandowska MA, Schwartz PJ, Insolia R, Pedrazzini M, Bussani E, Dagradi F, George AL Jr, and Pagani F
- Subjects
- Adult, Death, Sudden, Cardiac, ERG1 Potassium Channel, Female, Genetic Testing, Genotype, Humans, Introns, Lod Score, Male, Pedigree, Phenotype, RNA Splice Sites, RNA Splicing, Transcription, Genetic, Ether-A-Go-Go Potassium Channels genetics, Long QT Syndrome genetics, Point Mutation
- Abstract
Background: Genetic screening of long QT syndrome (LQTS) fails to identify disease-causing mutations in about 30% of patients. So far, molecular screening has focused mainly on coding sequence mutations or on substitutions at canonical splice sites., Objective: The purpose of this study was to explore the possibility that intronic variants not at canonical splice sites might affect splicing regulatory elements, lead to aberrant transcripts, and cause LQTS., Method: Molecular screening was performed through DHPLC and sequence analysis. The role of the intronic mutation identified was assessed with a hybrid minigene splicing assay., Results: A three-generation LQTS family was investigated. Molecular screening failed to identify an obvious disease-causing mutation in the coding sequences of the major LQTS genes but revealed an intronic A-to-G substitution in KCNH2 (IVS9-28A/G) cosegregating with the clinical phenotype in family members. In vitro analysis proved that the mutation disrupts the acceptor splice site definition by affecting the branch point (BP) sequence and promoting intron retention. We further demonstrated a tight functional relationship between the BP and the polypyrimidine tract, whose weakness is responsible for the pathological effect of the IVS9-28A/G mutation., Conclusions: We identified a novel BP mutation in KCNH2 that disrupts the intron 9 acceptor splice site definition and causes LQT2. The present finding demonstrates that intronic mutations affecting pre-mRNA processing may contribute to the failure of traditional molecular screening in identifying disease-causing mutations in LQTS subjects and offers a rationale strategy for the reduction of genotype-negative cases.
- Published
- 2009
- Full Text
- View/download PDF
45. All LQT3 patients need an ICD: true or false?
- Author
-
Schwartz PJ, Spazzolini C, and Crotti L
- Subjects
- Adult, Aged, Death, Sudden, Cardiac prevention & control, Decision Making, Exons, Female, Follow-Up Studies, Humans, Long QT Syndrome genetics, Long QT Syndrome metabolism, Male, Middle Aged, Muscle Proteins metabolism, NAV1.5 Voltage-Gated Sodium Channel, Pedigree, Polymerase Chain Reaction, Prognosis, Sodium Channels metabolism, DNA genetics, Defibrillators, Implantable, Electric Countershock instrumentation, Long QT Syndrome therapy, Muscle Proteins genetics, Mutation, Sodium Channels genetics
- Published
- 2009
- Full Text
- View/download PDF
46. Cardiac arrhythmias of genetic origin are important contributors to sudden infant death syndrome.
- Author
-
Schwartz PJ and Crotti L
- Subjects
- Catecholamines, Humans, Infant, Infant, Newborn, Mutation, Risk Factors, Stress, Physiological pathology, Tachycardia, Ventricular embryology, Adaptation, Physiological, Ryanodine Receptor Calcium Release Channel genetics, Stress, Physiological complications, Sudden Infant Death genetics, Tachycardia, Ventricular genetics
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.